文献速递头颈部肿瘤放疗放疗物理与技术

18F-FDG PET影像生物标志物模型预测头颈癌放疗后晚期口干症的验证

Validation of the 18F-FDG PET image biomarker model predicting late xerostomia after head and neck cancer radiotherapy.
PubMed 文献 · Radiother Oncol · 2023-01-03

本研究在137例头颈癌放疗患者独立验证队列中,评估治疗前对侧腮腺P90-SUV和Mean-SUV两种PET影像生物标志物对12个月患者报告中重度口干症的预测价值。PET-P90模型AUC为0.71,PET-Mean模型AUC为0.70,均优于仅含基线口干症和平均对侧腮腺剂量的基础模型(AUC=0.68),校准图显示各模型预测与实际发生率拟合良好。

要点

  • 验证队列137例,40%在放疗后12个月发生中重度口干症。
  • PET-P90模型AUC=0.71,PET-Mean模型AUC=0.70,基础模型AUC=0.68。
  • 加入PET影像生物标志物后预测性能较基础模型改善,校准良好。

核心结论

  • 在此验证队列中,将PET影像生物标志物加入基础模型后,对晚期口干症的预测得到改善。
  • 这支持了已发表的假设:PET影像生物标志物包含个体化信息,可作为晚期口干症的治疗前危险因素。

研究设计与样本

  • 独立验证队列研究,共纳入137例头颈癌放疗患者。
  • 预测终点为放疗后12个月患者报告的中重度口干症。
  • PET影像生物标志物从治疗前18F-FDG PET图像中提取。
  • 评估基础模型(仅含基线口干症和平均对侧腮腺剂量)及分别额外加入P90-SUV或Mean-SUV的模型,指标为判别能力(AUC)和校准(校准图)。

主要发现

  • 验证队列中40%的患者在12个月时发生中重度口干症。
  • PET-P90模型AUC=0.71,PET-Mean模型AUC=0.70,基础模型AUC=0.68。
  • 校准图显示所有测试模型的预测值与实际发生率拟合良好。

关键数值与推荐

  • PET-P90模型AUC=0.71,PET-Mean模型AUC=0.70,基础模型AUC=0.68。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Previously, PET image biomarkers (PET-IBMs) - the 90th percentile standardized uptake value (P90-SUV) and the Mean SUV (Mean-SUV) of the contralateral parotid gland (cPG) - were identified as predictors for late-xerostomia following head and neck cancer (HNC) radiotherapy. The aim of the current study was to assess in an independent validation cohort whether these pre-treatment PET-IBM can improve late-xerostomia prediction compared to the prediction with baseline xerostomia and mean cPG dose alone. MATERIALS AND METHODS: The prediction endpoint was patient-rated moderate-to-severe xerostomia at 12 months after radiotherapy. The PET-IBMs were extracted from pre-treatment 18 F-FDG PET images. The performance of the model (base model) with baseline xerostomia and mean cPG dose alone and models with additionally P90-SUV or Mean-SUV were tested in the current independent validation cohort. Specifically, model discrimination (area under the curve: AUC) and calibration (calibration plot) were evaluated. RESULTS: The current validation cohort consisted of 137 patients of which 40% developed moderate-to-severe xerostomia at 12 months. Both the PET-P90 model (AUC:PET-P90 = 0.71) and the PET-Mean model (AUC: PET-Mean = 0.70) performed well in the current validation cohort. Moreover, their performance were improved compared to the base model (AUC:base model= 0.68). The calibration plots showed a good fit of the prediction to the actual rates for all tested models. CONCLUSION: PET-IBMs showed an improved prediction of late-xerostomia when added to the base model in this validation cohort. This contributed to the published hypothesis that PET-IBMs include individualized information and can serve as a pre-treatment risk factor for late-xerostomia.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Li Y, Sijtsema NM, de Vette SPM, et al. Validation of the 18F-FDG PET image biomarker model predicting late xerostomia after head and neck cancer radiotherapy. Radiother Oncol. 2023. PMID: 36608769. doi:10.1016/j.radonc.2022.109458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。